Bharat Biotech International's rotavirus oral vaccine ROTAVAC️ has been introduced by Nigeria to immunise its children from the life-threatening diarrhoeal disease that affects millions of children worldwide.

Dr Krishna Ella, CMD, Bharat Biotech said, “This vaccine is now available in several countries across Asia, Africa, Latin America and the Middle East. Bharat Biotech will continue to play its role in researching, developing, and manufacturing novel vaccines, to lower the morbidity and mortality from infectious diseases and contribute towards the achievement of universal vaccine access."

ROTAVAC️ received WHO-Prequalification in January 2018.  Bharat Biotech developed the first generation, rotavirus vaccine, Rotavac under a Public-Private Partnership with the Department of Biotechnology, Government of India and 16 other international partners, making it the largest ever social innovation project for public health.

Rotavirus is one of the leading causes of diarrheal disease in the world and is responsible for over 40% of diarrhoea in children. It accounts for about 215,000 of the 525,000-under-5 mortality worldwide each year that are attributed to diarrheal diseases, making it the most common cause of severe diarrhoea.